Jump to content

N-acetyltransferase 2

From Wikipedia, the free encyclopedia

This is the current revision of this page, as edited by Trilotat (talk | contribs) at 15:14, 30 July 2023 (corrected authors in a ref, added authorlink). The present address (URL) is a permanent link to this version.

(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
NAT2
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesNAT2, AAC2, NAT-2, PNAT, N-acetyltransferase 2, N-acetyltransferase 2 (arylamine N-acetyltransferase)
External IDsOMIM: 612182; MGI: 97279; HomoloGene: 115468; GeneCards: NAT2; OMA:NAT2 - orthologs
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_000015

NM_008673

RefSeq (protein)

NP_000006

NP_032699

Location (UCSC)Chr 8: 18.39 – 18.4 MbChr 8: 67.93 – 67.94 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

N-acetyltransferase 2 (arylamine N-acetyltransferase), also known as NAT2, is an enzyme which in humans is encoded by the NAT2 gene.[5]

Function

[edit]

This gene encodes a type of N-acetyltransferase. The NAT2 isozyme functions to both activate and deactivate arylamine and hydrazine drugs and carcinogens. Polymorphisms in this gene are responsible for the N-acetylation polymorphism in which human populations segregate into rapid, intermediate, and slow acetylator phenotypes. Polymorphisms in NAT2 are also associated with higher incidences of cancer and drug toxicity. A second arylamine N-acetyltransferase gene (NAT1) is located near NAT2.[6]

Phenotype prediction

[edit]

The NAT2 acetylator phenotype can be inferred from NAT2 genotype (a combination of SNPs observed in a given individual).[7][8][9][10]

References

[edit]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000156006Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000025588Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DA, Grant DM, Hein DW, Lin HJ, Meyer UA, Relling MV, Sim E, Suzuki T, Yamazoe Y (February 1995). "Nomenclature for N-acetyltransferases". Pharmacogenetics. 5 (1): 1–17. doi:10.1097/00008571-199502000-00001. PMID 7773298.
  6. ^ "Entrez Gene: NAT2 N-acetyltransferase 2 (arylamine N-acetyltransferase)".
  7. ^ "NAT2PRED: a computational predictor of the human N-AcetylTransferase-2 (NAT2) acetylator phenotype". State University of New York – Albany. Archived from the original on 2009-05-22. Retrieved 2009-04-30.
  8. ^ Kuznetsov IB, McDuffie M, Moslehi R (May 2009). "A web server for inferring the human N-acetyltransferase-2 (NAT2) enzymatic phenotype from NAT2 genotype". Bioinformatics. 25 (9): 1185–6. doi:10.1093/bioinformatics/btp121. PMC 2672629. PMID 19261719.
  9. ^ Agúndez JA (2008). "Polymorphisms of human N-acetyltransferases and cancer risk". Curr. Drug Metab. 9 (6): 520–31. doi:10.2174/138920008784892083. PMID 18680472.
  10. ^ Agúndez JA (2008). "N-acetyltransferases: lessons learned from eighty years of research". Curr. Drug Metab. 9 (6): 463–4. doi:10.2174/138920008784892146. PMID 18680465.

Further reading

[edit]
[edit]